Incentives for Clinical Decisions Where Evidence Is Lacking∗  by Heidenreich, Paul
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 5 , N O . 9 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 1 . 0 1 5EDITORIAL COMMENTIncentives for Clinical Decisions Where
Evidence Is Lacking*
Paul Heidenreich, MDT here is concern that much of health carespending in the United States is wasteful giventhe poor correlation between cost of care and
patient access, outcomes, and satisfaction. Hospitals
are the usual targets for reducing unnecessary
spending, given the large percentage of care provided
to inpatients.Medicare often has succeeded in lowering
hospital expenses through interventions such as
paying hospitals a single lump sum for an episode of
care (diagnostic-related group for hospitalization),
penalizing hospitals for “excess” readmissions, and
paying less for inpatient procedures if they can be per-
formed in the outpatient setting. However, physicians
controlmuch of the cost of care through their treatment
decisions, and the wide variety of physician incentives
in place today makes it difﬁcult to predict future
resource use. The study by Jones et al. (1) in this issue
of the Journal demonstrates how this physician “wild
card” can change the balance sheet dramatically.SEE PAGE 920The authors note that their study of peripheral
vascular interventions (PVI) for peripheral arterial
disease (PAD) was prompted by Medicare’s decision
to increase reimbursement for outpatient PVI to
reduce the number of inpatient procedures. They
found that this change by Medicare had the intended
effect of decreasing inpatient use. However, it also
was followed by a large increase in the use of the
more expensive atherectomy procedure. Overall costs
were likely lower than without the change in reim-
bursement, but the rise in atherectomy use was likely
unexpected and unintended.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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contents of this paper to disclose.PAD has been a focus of Medicare given its high
prevalence (15% to 20% among those patients
>70 years of age) and the high cost of PVI. Over the past
decade, there has been a large increase in the use of
PVI. However, lower extremity disease has many
challenges for percutaneous procedures including
frequent chronic total exclusions and diffuse athero-
sclerotic burden. The limited technical ability of
balloon angioplasty to improve these lesions has led
to the development of new technologies using athe-
rectomy. In the last few years, a large number of
atherectomy-based technologies have been developed
to improve the ability to open chronic total occlusions.
Unfortunately, there are limited data comparing
the endovascular options, so we do not yet know
which procedure is best for which patient. A 2010
systematic review could not ﬁnd a signiﬁcant clinical
beneﬁt of stenting compared with angioplasty,
although technical success was higher with stenting
(2). In 2014, the Cochrane Review identiﬁed only 4
small randomized trials of atherectomy for PAD (3).
They concluded that the data were poor and that
“there was no evidence for superiority of atherec-
tomy over angioplasty on any outcome” (3). Given the
limited data, it is perhaps not surprising that clinical
practice guidelines for PAD are silent on which form
of PVI to use. The recently created appropriateness
criteria for treatment of PAD also do not provide
guidance for use of atherectomy or other forms of
PVI (4). They note that there were no controlled
studies showing improvement in long-term patency
or clinical outcomes with atherectomy.
If clinical trials are lacking, thenwhat is the cause of the
increase in atherectomy use? Some would argue that
ﬁnancial incentives will ﬁll any outcome data vacuum. As
the authors note, Medicare reimbursement rates have
provided a clear incentive for practices to increase the use
ofoutpatientprocedures.However,physiciansperforming
the procedure in hospital also have a ﬁnancial incentive to
perform atherectomy. For femoral/popliteal atherectomy
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929performed in a facility, Medicare pays the physician
approximately $650 for atherectomy, $530 for stenting,
and $480 for angioplasty alone. The difference in facility
fees between atherectomy and angioplasty is signiﬁcantly
greater, although it is unclear to what extent Medicare
reimbursement is higher than actual practice cost.
An increase in Medicare reimbursement is usually
followed by an increase in use. A study using Medicare
price changes found that, on average, a 2% increase in
reimbursement leads to a 3% increase in use (5). The
effect of reimbursement on use was greatest for
elective procedures, such as coronary angiography,
and would likely apply to atherectomy in PAD.
However, there are noneconomic factors at work
that may be even more important. A desire to be at
the forefront of one’s specialty is part of the culture
for most physicians, and being proﬁcient in the latest
technology is highly desirable for specialists. Others
have documented the importance of culture on
resource use for generalists as well. Internists and
family practitioners were more likely to order non-
recommended cancer screening, see patients more
frequently, and be more aggressive in ordering tests if
they resided in areas of the country with a high
spending “culture” (6).
The hospital or practice has its own economic
incentive even if it is not felt by the individual physi-
cian. Patients often associate quality and best outcome
with available technology. As with robotic surgery,
hospitals and practices are often advertising their
ability to provide the latest endovascular technologies.
Somewill say that capitationwill solve this problem,
as physicians will no longer increase income by doing
more expensive procedures. However, in the past, the
economic effect of managed care capitation has been
small. In a survey from 10 years ago,managed care only
had small effects on the intensity of ordering tests
when compared with other physician characteristics,
such as board certiﬁcation (less ordering), years in
practice (more years, more ordering), and size of group
(larger group, less ordering) (7).
Physicians should not be expected to choose the
most cost-effective treatment for society. Both a
lack of knowledge and a discomfort with making
decisions on the basis of cost effectiveness (8) make
this unrealistic for most physicians. The American
College of Cardiology/American Heart Associationrecently decided to report the published data on
value (cost-effectiveness) alongside the recommen-
dations for beneﬁt in future guidelines (9). However,
the main effect of the value information in the
guidelines may be on payers who will decide which
treatments should be ﬁrst line.
What should be done in the absence of outcomes
data? Although many authors have called for more
randomized trials, there is little incentive to conduct
them. Currently, there are 2 ongoing randomized trials
of atherectomy where a patient outcome (symptom or
event) is a primary outcome (although only 553 pa-
tients are expected to be enrolled across both trials).
Unfortunately, for those trying to control cost, the U.S.
Food and Drug Administration has a relatively low bar
for approving devices. Occasionally, approved prod-
ucts are found to be harmful once patient outcomes
are ﬁnally measured (e.g., metal-on-metal hip
replacements). Even if patients are not harmed by new
technology, Medicare cannot consider whether a new
technology is a good or bad value. Furthermore,
comparative-effectiveness studies funded by the
government through the Patient Centered Outcomes
Research Initiative, by law, cannot evaluate cost and
value.
What Medicare can and should do is require a
registry for all new technologies that are without
sufﬁcient randomized trial data demonstrating
improved patient outcome. Such registries are
required for implantable deﬁbrillators and percuta-
neous aortic valve replacements despite better
outcome data than for atherectomy. Although
mandated registries are impractical for every proce-
dure lacking in evidence, the substantial budgetary
effect of PVI should make it a top priority.
For the foreseeable future, physicians will have
strong incentives to use the latest atherectomy devices
for PAD. Economics for the physician and practice are
favorable, technical success keeps improving, and
patients will always want the latest technology. Those
paying insurance premiums and taxes can only hope
that the beneﬁts to patients will be worth the cost.
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